Immuno-Oncology | Specialty

CHMP Recommends T-VEC Approval for Melanoma

October 23rd 2015

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

Dr. Reidy Lagunes on the Potential of Immunotherapy in NETs

October 21st 2015

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

October 17th 2015

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Nivolumab Investigator Discusses Expanded Approval, Compares With Pembrolizumab

October 16th 2015

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

TILs Emerge as Robust Biomarker, Shed Light on Immunotherapy Potential in TNBC

October 14th 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma

October 12th 2015

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Combining TKIs and Immunotherapies in GIST

October 9th 2015

Emerging Therapies for Gastrointestinal Stromal Tumors

October 9th 2015

Therapeutic Options for Progressive GIST

October 9th 2015

Tyrosine Kinase Inhibition in Gastrointestinal Stromal Tumors

October 9th 2015

Multidisciplinary Treatment for GIST

October 9th 2015

Factors Impacting Neoadjuvant Treatment of GIST

October 9th 2015

Assessing Response to Imatinib in GIST

October 9th 2015

Adjuvant Imatinib for Gastrointestinal Stromal Tumor

October 9th 2015

Risk Stratification and Prognostic Factors in GIST

October 9th 2015

Gastrointestinal Stromal Tumor Diagnosis

October 9th 2015

Medication, Imaging, and Surgery Advancements for GIST

October 9th 2015

Evolving Understanding of Gastrointestinal Stromal Tumors

October 9th 2015

FDA Expands Nivolumab Lung Cancer Approval

October 9th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab for patients with nonsquamous non–small cell lung cancer previously treated with platinum-based chemotherapy.

PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma

October 7th 2015

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.